David Morrow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Morrow has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Abidemi Olayinka
Dublin City University
1 shared publication - Andreu Llobera
Institut de Microelectrònica de Barcelona (IMB-CNM, CSIC), SPAIN
1 shared publication Anton Ussi
EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, Netherlands
1 shared publication- Claire Molony
Dublin City University
1 shared publication - Damien King
Dublin City University
1 shared publication - David Kernan
Dublin City University
1 shared publication
Latest Publications
- Open Access
Disease-relevant single cell photonic signatures identify S100β stem cells and their myogenic progeny in vascular lesions
A hallmark of subclinical atherosclerosis is the accumulation of vascular smooth muscle cell (SMC)-like cells leading to intimal thickening and lesion formation. While medial SMCs contribute to vascular lesions, the involvement of resident vascular stem cells (vSCs) remains unclear. We evaluated single cell photonics as a discriminator of cell phenotype in vitro before the presence of vSC within vascular lesions was assessed ex vivo using supervised machine learning and further validated using lineage tracing analysis. Using a novel lab-on-a-Disk (Load) platform, label-free single cell photonic emissions from normal and injured vessels ex vivo were interrogated and compared to freshly isolated aortic SMCs, cultured Movas SMCs, macrophages, B-cells, S100β + mVSc, bone marrow derived mesenchymal stem cells (MSC) and their respective myogenic progeny across five broadband light wavelengths (λ465 – λ670 ± 20 nm). We found that profiles were of sufficient coverage, specificity, and quality to clearly distinguish medial SMCs from different vascular beds (carotid vs aorta), discriminate normal carotid medial SMCs from lesional SMC-like cells ex vivo following flow restriction, and identify SMC differentiation of a series of multipotent stem cells following treatment with transforming growth factor beta 1 (TGF-β1), the Notch ligand Jaggedl, and Sonic Hedgehog using multivariate analysis, in part, due to photonic emissions from enhanced collagen III and elastin expression. Supervised machine learning supported genetic lineage tracing analysis of S100β + vSCs and identified the presence of S100β + vSC-derived myogenic progeny within vascular lesions. We conclude disease-relevant photonic signatures may have predictive value for vascular disease.
Open AccessDisease-relevant single cell photonic signatures identify S100β stem cells and their myogenic progeny in vascular lesions
A hallmark of subclinical atherosclerosis is the accumulation of vascular smooth muscle cell (SMC)-like cells leading to intimal thickening and lesion formation. While medial SMCs contribute to vascular lesions, the involvement of resident vascular stem cells (vSCs) remains unclear. We evaluated single cell photonics as a discriminator of cell phenotype in vitro before the presence of vSC within vascular lesions was assessed ex vivo using supervised machine learning and further validated using lineage tracing analysis. Using a novel lab-on-a-Disk (Load) platform, label-free single cell photonic emissions from normal and injured vessels ex vivo were interrogated and compared to freshly isolated aortic SMCs, cultured Movas SMCs, macrophages, B-cells, S100β + mVSc, bone marrow derived mesenchymal stem cells (MSC) and their respective myogenic progeny across five broadband light wavelengths (λ465 – λ670 ± 20 nm). We found that profiles were of sufficient coverage, specificity, and quality to clearly distinguish medial SMCs from different vascular beds (carotid vs aorta), discriminate normal carotid medial SMCs from lesional SMC-like cells ex vivo following flow restriction, and identify SMC differentiation of a series of multipotent stem cells following treatment with transforming growth factor beta 1 (TGF-β1), the Notch ligand Jaggedl, and Sonic Hedgehog using multivariate analysis, in part, due to photonic emissions from enhanced collagen III and elastin expression. Supervised machine learning supported genetic lineage tracing analysis of S100β + vSCs and identified the presence of S100β + vSC-derived myogenic progeny within vascular lesions. We conclude disease-relevant photonic signatures may have predictive value for vascular disease.
- Open Access
- 25 September 2017
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 5, 55
Addressing Pressing Needs in the Development of Advanced Therapies
The commercial development of Advanced Therapy Medicinal Products (ATMPs) represents great opportunity for therapeutic innovation, but is beset by many challenges for its developers. Although the ATMP field continues to progress at a rapid pace, evidenced by the increasing number of clinical trials conducted over the last few years, several factors continue to complicate the introduction of ATMPs as a curative treatment for multiple disease types, by blocking their translational pathway from research to the patient. While several recent publications (1-3) as well as an Innovative Medicines Initiative (IMI) consultation (4) this year have highlighted the major gaps in ATMP development, with manufacturing, regulatory and reimbursement issues at the forefront, there remains to be formulated a coherent strategy to address these by bringing the relevant stakeholders to a single forum, whose task it would be to design and execute a delta plan to alleviate the most pressing bottlenecks. This white paper focuses on two of the most urgent areas in need of attention in ATMP development, namely manufacturing and reimbursement, and promotes the concept of innovation-dedicated research infrastructures to support a multi-sector approach for ensuring the successful development, entry and ensuing survival of ATMPs in the healthcare market.
- 25 September 2017
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 5, 55
Open AccessAddressing Pressing Needs in the Development of Advanced Therapies
The commercial development of Advanced Therapy Medicinal Products (ATMPs) represents great opportunity for therapeutic innovation, but is beset by many challenges for its developers. Although the ATMP field continues to progress at a rapid pace, evidenced by the increasing number of clinical trials conducted over the last few years, several factors continue to complicate the introduction of ATMPs as a curative treatment for multiple disease types, by blocking their translational pathway from research to the patient. While several recent publications (1-3) as well as an Innovative Medicines Initiative (IMI) consultation (4) this year have highlighted the major gaps in ATMP development, with manufacturing, regulatory and reimbursement issues at the forefront, there remains to be formulated a coherent strategy to address these by bringing the relevant stakeholders to a single forum, whose task it would be to design and execute a delta plan to alleviate the most pressing bottlenecks. This white paper focuses on two of the most urgent areas in need of attention in ATMP development, namely manufacturing and reimbursement, and promotes the concept of innovation-dedicated research infrastructures to support a multi-sector approach for ensuring the successful development, entry and ensuing survival of ATMPs in the healthcare market.